Skip to main content
. 2010 May 17;12(4):527–534. doi: 10.1038/aja.2010.21

Figure 1.

Figure 1

Inhibition of the canonical extracellular signal regulated protein kinases (ERK) phosphorylation by sorafenib treatment. Prostate cancer cells were exposed to the drug at the indicated concentrations for 4 h. The cells were then lysed and the lysates were analyzed by Western blot for phosphorylated-ERK (p-ERK), using total ERK levels as an internal control. The morphological pictures represent PC-3, LNCap, and DU145 cells treated with 10 μmol L−1 sorafenib for 24 h.